Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 09, 2020 01:00 ET | Source: ObsEva SA

ObsEva appoints Brian O’Callaghan as Chief Executive Officer

Geneva, Switzerland and Boston, MA – November 9, 2020 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve...
November 05, 2020 01:00 ET | Source: ObsEva SA

ObsEva Announces Third Quarter 2020 Financial Results and Business Update

Positive Phase 3 PRIMROSE 1 and 2 trial results of linzagolix for the treatment of heavy menstrual bleeding due to uterine fibroids presented in late breaking session of ASRM Virtual...
November 02, 2020 01:00 ET | Source: ObsEva SA

ObsEva SA hosts live symposium and presents oral communication at the SEUD Online Week November 3 - 6, 2020

Geneva, Switzerland and Boston, MA – 2 November, 2020 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve...
October 22, 2020 01:00 ET | Source: ObsEva SA

ObsEva SA Presented Two Late-Breaking Posters at the ASRM 2020 Virtual Scientific Congress October 17-21

Geneva, Switzerland and Boston, MA – October 22, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s...
October 20, 2020 01:00 ET | Source: ObsEva SA

ObsEva SA Presented Nolasiban Poster at the ASRM 2020 Virtual Scientific Congress October 17-21

Geneva, Switzerland and Boston, MA – October 20, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s...
September 08, 2020 01:00 ET | Source: ObsEva SA

ObsEva SA to present at the H.C Wainwright 22nd Annual Global Investment Virtual Conference, September 14-16, 2020

Geneva, Switzerland and Boston, MA – September 8, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s...
September 03, 2020 17:00 ET | Source: ObsEva SA

ObsEva Announces $20.0 Million Underwritten Offering and Concurrent Private Placement Priced At-The-Market of Common Shares and 15-Month Purchase Warrants for Potential Additional Gross Proceeds of $23.9 Million

GENEVA, Switzerland and BOSTON, MA (September 3, 2020) – ObsEva SA (NASDAQ: OBSV) (SIX: OBSN) (“ObsEva” or the “Company”), a clinical-stage biopharmaceutical company developing and commercializing...
August 07, 2020 01:00 ET | Source: ObsEva SA

ObsEva SA to present at the Wedbush PacGrow Healthcare Virtual Conference, August 11 – 12, 2020

Geneva, Switzerland and Boston, MA – August 7, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s...
August 06, 2020 01:00 ET | Source: ObsEva SA

ObsEva Announces Second Quarter 2020 Financial Results and Business Update

Primary endpoint successfully met in Phase 3 PRIMROSE 1 trial of linzagolix for the treatment of heavy menstrual bleeding due to uterine fibroids Phase 3 data from PRIMROSE 2 trial demonstrated...
July 15, 2020 01:00 ET | Source: ObsEva SA

ObsEva SA Awarded Clinical Science Award for Oral Presentation at ESHRE Virtual 36th Annual Meeting, July 2020

Geneva, Switzerland and Boston, MA – July 15, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s...